Jane Street
ENGN icon

Jane Street’s enGene Therapeutics ENGN Stock Holding History

Jane Street’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.9K Buy
+19,000
New +$77.5K ﹤0.01% 11075

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Jane Street's ENGN Position: Q2 2026 in Review

Jane Street increased its enGene Therapeutics (ENGN) stake by 145% in Q2 2026, buying an estimated $923K and bringing the position to 382,459 shares worth $662K. The position accounts for ﹤0.01% of the portfolio, ranked #7400.

Jane Street first reported a position in ENGN in Q4 2024 and has held it in 4 quarters since. The position peaked at $1.06M in Q1 2026. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Jane Street held 382,459 shares of enGene Therapeutics worth $662K as of Q2 2026.
  • Jane Street bought 226,458 enGene Therapeutics shares in Q2 2026, an estimated $923K.
  • enGene Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #7400 holding.
  • Jane Street first reported a position in enGene Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Jane Street's enGene Therapeutics position peaked at $1.06M in Q1 2026.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.